500 mcg of bpc 157 BPC157 500mcg BPC-157 (500 MCG) - Sigma

Both compounds are expensive

In some aspects, the invention provides methods of treating dementia patients at various stages of dementia, and/or of slowing and/or preventing the progression of dementia to later stages of dementia, or even or reversing the "staging" from advanced to moderate or early, or from moderate to early, stage

Frequently Asked Questions Is ARG-BPC-157 different from standard BPC-157

Anecdotal reports from users have included: Commonly Reported: Injection site pain, redness, or swelling Mild dizziness Nausea Fatigue or drowsiness Less Commonly Reported: Anxiety or mood changes Heart palpitations Insomnia Loss of appetite Depression or anhedonia The FDA has noted that BPC-157 may pose an immunogenicity risk (triggering an immune response)